Dr. Felipe Samaniego Has Been Recognized Among the Top in His Industry by the Expert Network©

Press Release (ePRNews.com) - Houston, TX - Jun 15, 2017 - Dr. Felipe Samaniego, Cancer Researcher & Physician, MD Anderson Cancer Center, has joined The Expert Network©, an invitation-only service for distinguished professionals. Dr. Samaniego has been chosen as a Distinguished Doctor based on peer reviews and ratings, numerous recognitions, and accomplishments achieved throughout his career.

Over the course of 20 years, Dr. Samaniego has worked on laboratory-based studies to optimize therapy of patients with lymphoma. The ultimate goal is to step beyond chemotherapy and develop new therapies that take advantage of the power of immunotherapy and targeting drug therapies. He noted:

“Cancer therapies based on immunotherapy can now bring lymphoma remissions without the toxicity often associated with chemotherapy. The days of toxicity will soon be over.”

Felipe Samaniego, M.D., Cancer Researcher & Physician, MD Anderson Cancer Center, Houston

“Cancer therapies based on immunotherapy can now bring lymphoma remissions without the toxicity often associated with chemotherapy. The days of toxicity will soon be over.”

In his role as a cancer researcher, Dr. Samaniego is investigating the driving forces that cause lymphoma. His team has identified markers that predict clinical outcomes and these markers are being used to personalize therapy according to each type of lymphoma. With over 20 different types of lymphoma, he plans to prospectively identify the best treatment type for each individual patient.

His scientific team has provided education and further training for young scientists. Trainees from his laboratory go on to hold key positions at medical centers and biotech companies throughout the world. He continues to recruit young talent to MD Anderson Cancer Center where they join his research team to hone their skills and advance their careers as cancer investigators.

Dr. Samaniego’s team of scientists has found that not all lymphoma cells in a tumor are the same. Tumors contain a few cells that have unique properties that allow the cells to regrow and generate a whole tumor. These are properties of cancer stem cells and despite therapy, cancer stem cells manage to survive, proliferate and become the source of relapse tumors. The role of a stem cell is similar to the relationship of a queen bee and the worker bees in a hive. If a worker bee finds a way to kill the queen bee, he will have shut off the source of new bees and eliminate the hive. His research is set out to identify vulnerable sites on lymphoma stem cells and develop insightful ways to kill the few stem cells that control the whole lymphoma tumor.

Even the effectiveness of new targeting drugs, such as ibrutinib for lymphoma, decreases over the course of time. Dr. Samaniego has found that development of resistance to ibrutinib is acquired through generation of new lymphoma cell proliferation signals that keep cells alive. He anticipates screening of the resistant lymphoma cells will reveal which drugs are active on this resistant type of lymphoma cells.

For more information, visit Dr. Samaniego’s profile on the Expert Network here: https://expertnetwork.co/members/felipe-samaniego,-md/3689affe00e4e4ff

The Expert Network© has written this news release with approval and/or contributions from Dr. Felipe Samaniego. The Expert Network© is an invitation-only reputation management service that is dedicated to helping professionals stand out, network, and gain a competitive edge. The Expert Network selects a limited number of professionals based on their individual recognitions and history of personal excellence.

Source : The Expert Network©
Business Info :
Expert Network

You may also like this  

DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login